Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,767 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06710379RecruitingPhase 1
Testing ADRX-0405 for advanced solid tumors
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
Duarte, CaliforniaAges 18 years+ - NCT07204340RecruitingPhase 1
TLN-372 for advanced KRAS-mutant solid tumors
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
Birmingham, AlabamaAges 18 years+ - NCT05749432RecruitingPhase 1
Testing a new medicine for advanced solid tumors
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
Beijing, Beijing MunicipalityAges 18–65 - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Duarte, CaliforniaAges 18 years+ - NCT06940349RecruitingPhase 1/Phase 2
Palbociclib and sunitinib for advanced solid tumors
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Petah TikvaAges 18 years+ - NCT07190469RecruitingPhase 1
PQ203 for advanced solid tumors like triple-negative breast cancer
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Houston, TexasAges 18 years+ - NCT06944457RecruitingPhase 1
Safety Study of MPD-1 for Advanced Solid Tumors
This trial tests a new drug called MPD-1 for people with advanced solid tumors that have not responded to standard treatments. It focuses on patients with specific genetic changes (KRAS mutation or PTEN loss) to see if the drug is safe and how the body processes it.
SeoulAges 19–75 - NCT07151040RecruitingPhase 1/Phase 2
Testing TH9619 for advanced solid tumors
This trial tests a new drug called TH9619 for people with advanced cancers of the colon, head and neck, lung, or stomach. It aims to see if the drug is safe and works against tumors that have already been treated with chemotherapy.
VillejuifAges 18 years+ - NCT07128303RecruitingPhase 1
Study of a new drug for advanced solid tumors with a specific genetic feature
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT07128914RecruitingPhase 1
Study of GO306 for advanced solid tumors
This trial tests a new drug called GO306 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have certain cancers like breast, bladder, colorectal, kidney, ovarian, or neuroendocrine tumors, and you have malignant ascites (fluid buildup in the belly) that needs treatment.
Hefei, AnhuiAges 18 years+ - NCT06968572RecruitingPhase 1
New drug for MTAP-deleted solid tumors
This trial tests a new experimental drug (HSK41959) for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and effective for tumors that no longer respond to standard treatments.
Guiyang, GuizhouAges 18 years+ - NCT07098052RecruitingPhase 1
Study of HDM2020 for advanced solid tumors
This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07102004RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
BeijingAges 18 years+ - NCT07092748RecruitingPhase 1
Testing HS387 for advanced solid tumors
This trial tests a new drug called HS387 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how well it works.
Hangzhou, ZhejiangAges 18–75 - NCT07070232RecruitingPhase 1/Phase 2
Testing a new drug BNT326 for advanced cancers
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
Phoenix, ArizonaAges 18 years+ - NCT07069062RecruitingPhase 1/Phase 2
Study of HY0001a for Advanced Solid Tumors
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07071103RecruitingPhase 2
Low-dose radiation and immunotherapy for resistant solid tumors
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
Shantou, GuangdongAges 18–80 - NCT07055594RecruitingPhase 1/Phase 2
Study of SOA101 for advanced solid tumors
This trial tests a new drug called SOA101 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink tumors.
TaichungAges 18 years+ - NCT07050641RecruitingPhase 1/Phase 2
Study of SCTB39-1 for advanced solid tumors
This trial tests a new drug called SCTB39-1 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: first finding the right dose, then testing how well it works.
BeijingAges 18 years+ - NCT07050459RecruitingPhase 1
Study of SIM0686 for advanced solid tumors
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07029399RecruitingPhase 1
Study of NKT5097 for advanced solid tumors
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07032298RecruitingPhase 1
Testing SSGJ-612 for advanced solid tumors with HER2
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
Luoyang, HenanAges 18–75
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,767 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.